Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02162472 · ClinicalTrials.gov registry record
Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis
A clinical trial of Psoriasis, sponsored by Northwestern University.
- Completed
- Registry status
- 19
- Enrollment target
- 1
- Study location
NCT02162472: Completed study of Psoriasis, sponsored by Northwestern University.
NCT02162472 is a study of Psoriasis that has completed, run by Northwestern University. The registered enrollment target is 19 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02162472, a study of Psoriasis, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to determine if videocapillaroscopy could be used as an objective and reliable method to assess psoriasis severity and to document improvement during treatment by measuring changes in vascular features.
Primary Outcome
The primary objective is to determine if videocapillaroscopy could be used as an objective and reliable method to assess psoriasis severity and to document improvement during treatment by measuring changes in vascular features.
Conditions Studied
Study Locations (1)
Illinois
- Northwestern University, Department of Dermatology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-07 |
| Est. Completion | 2021-12-31 |
What the finished NCT02162472 record still lists
NCT02162472 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 0 interventions.
NCT02162472 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02162472 about?
NCT02162472 is a clinical study titled "Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis". The aim of this study is to determine if videocapillaroscopy could be used as an objective and reliable method to assess psoriasis severity and to document improvement during treatment by measuring changes in vascular features.
What is the current status of trial NCT02162472?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2015-07. Estimated completion is 2021-12-31.
What conditions does trial NCT02162472 study?
This clinical trial studies the following conditions: Psoriasis.
Who is sponsoring clinical trial NCT02162472?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02162472 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02162472's enrollment target sits among peer trials
19 111th of 125 higher than 14 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia